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Abstract
Aim of the Study
Podocalyxin-like 1 is a transmembrane glyco-protein whose overexpression associates in
many cancers with poor prognosis and unfavorable clinicopathological characteristics. Until
now, its prognostic value has never been studied in pancreatic ductal adenocarcinoma
(PDAC). The aim of this study was to investigate podocalyxin expression in PDAC by a
novel monoclonal antibody and a commercially available polyclonal antibody.
Patients and Materials
With tissue microarrays and immuno-histochemistry, podocalyxin expression evaluation in-
volved 168 PDAC patients. The associa-tions of the podocalyxin tumor expression with
clinicopathological variables were explored by Fisher’s exact test and the linear-by-linear
test. Survival analyses were by Kaplan-Meier anal-ysis and the Cox proportional hazard
model.
Results
The polyclonal antibody revealed membranous podocalyxin expression in 73 (44.0%) spec-
imens and the monoclonal antibody was highly expressed in 36 (21.8%) cases. Membra-
nous expression by the polyclonal antibody was associated with T classification (p=0.045)
and perineural invasion (p=0.005), and high expression by the mono-clonal antibody with
poor differentiation (p=0.033). High podocalyxin expression associated significantly with
higher risk of death from PDAC by both the polyclonal antibody (hazard ratio (HR) = 1.62;
95% confidence interval (CI) 1.12-2.33; p=0.01) and the monoclonal antibody (HR = 2.10,
95% CI 1.38-3.20; p<0.001). The results remained significant in multivariate analysis, ad-
justed for age, gender, stage, lymph node ratio (/< 20%), and perivascular invasion (re-
spectively as HR = 2.03; 95% CI 1.32-3.13, p=0.001; and as HR = 2.36; 95% CI 1.47-3.80,
p<0.001).
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Conclusion
We found podocalyxin to be an independent factor for poor prognosis in PDAC. To our
knowledge, this is the first such report of its prognostic value.
Introduction
The prognosis of pancreatic ductal adenocarcinoma (PDAC) is extremely poor, with overall
5-year survival less than 5% [1,2]. Finland has about 1000 new cases per year, and PDAC is the
third leading cause of cancer-related death [1]. In the United States, PDAC is the fourth leading
cause of cancer-related mortality, causing annually about 40,000 deaths [2]. Despite improve-
ments in management, the survival rate has not improved markedly over the last few decades
[2]. At diagnosis, roughly 10% has localised disease and 25% regional disease [2]. Radical surgi-
cal resection is the only curative treatment, but disease is unresectable in about 80% of the
cases [3]. Although overall survival is poor, there is a great variation between patients of the
same stage, for whom new biomarkers might help in predicting prognosis. Research on poten-
tial biomarkers has been intense, but it still lacks good prognostic markers [4–6].
Podocalyxin-like 1 (PODXL), a transmembrane glycoprotein closely related to the hemato-
poietic stem cell marker CD34 and to endoglycan [7], regulates cell-to-cell adhesion through
charge-repulsive effects but also contributes to cell morphology [7]. PODXL is normally ex-
pressed in hematopoietic progenitor cells [8], vascular endothelial cells [9], and renal podocytes
[10]. First identified in the kidney, it helps there to maintain filtration pathways [11]. Loss of
normal PODXL expression is associated with glomerulopathies—mainly with nephrotic syn-
drome [12].
PODXL overexpression has been described in several cancer types including leukemia and
breast, colorectal, urothelial bladder, hepatocellular and prostate cancers [13–19]. In renal cell
carcinoma, breast, and colorectal cancers, PODXL overexpression is an independent factor for
poor outcome [14–16,20]. Whether PODXL is a marker of poor prognosis also in pancreatic
cancer, remains unclear. It has been shown that PDAC cells are generally positive for PODXL,
but other adenocarcinomas of the biliary and gastrointestinal tract are mainly negative [21].
Dallas et al. concluded that sialofucosylated PODXL is overexpressed by metastatic pancreatic
cancer cells [22]. Furthermore, membranous PODXL expression has been suggested to corre-
late with poor prognosis in colorectal and urothelial bladder cancers [15–17]. Recently Kaprio
et al. showed that high cytoplasmic expression of PODXL by a novel monoclonal antibody
(mAb) is a marker of poor prognosis in colorectal cancer [23].
In this study we examined the prognostic value of PODXL expression in PDAC, comparing
PODXL expression by our in-house HES9 mAb with a commercially available polyclonal anti-
body (pAb).
Materials and Methods
Patients
The study population comprised 189 consecutive PDAC patients surgically treated in 2000–
2011 at the Department of Surgery, Helsinki University Hospital. Median age at operation was
64 (range 39–84) years. There were 21 patients, who had received neoadjuvant chemotherapy.
Those were excluded from the study. Survival data and cause of death of the patients were ob-
tained from patients’ records, Statistics Finland, and the Finnish Population Registry. This
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study complies with the declaration of Helsinki and was approved by the Surgical Ethics Com-
mittee of Helsinki University Central Hospital (Dnro HUS 226/E6/06, extension TMK02 §66
17.4.2013) and the National Supervisory Authority of Welfare and Health gave the permission
to use tissue samples without individual informed consent in this retrospective study (Valvira
Dnro 10041/06.01.03.01/2012).
Preparation of tumor tissue microarrays
Formalin-fixed and paraffin-embedded surgical tissue samples were collected from the archives
of the Department of Pathology, Helsinki University Hospital. Tissue specimens suitable for
immunohistochemical evaluation were available from 168 patients. 15 patients were excluded
due to inadequate or missing samples. All samples were re-evaluated by experienced patholo-
gists (J.H. and S.N.) for confirmation of the histopathological diagnosis of PDAC. Most repre-
sentative regions of tumor specimens were defined and tumor area was marked on
hematoxylin- and eosin-stained tumor slides to prepare the TMA. Two 1.0-mm cores were
taken from each tumor with a semiautomatic tissue microarrayer (Tissue Arrayer 1, Beecher
Instruments Inc., Silver Spring, MD, USA).
Antibodies
The novel monoclonal in-house antibody (HES9) used in this study recognizes amino acid resi-
dues 189–192 of PODXL. The polyclonal antibody (HPA 2110, Atlas Antibodies, Stockholm,
Sweden) recognizes amino acid residues 278–415. The specificity of the polyclonal antibody
has been validated by Western blotting and protein arrays, and PODXL protein expression
mapped by immunohistochemistry in normal tissues and common cancers [24,25]. It has also
served in other biomarker studies on colorectal, urothelial bladder and pancreatic cancer
[16,17,21].
The monoclonal antibody has been previously described in detail [23]. In brief, mice
were immunized with the undifferentiated human embryonic (hES) stem cell line SA167 (Cel-
lartis, Göteborg, Sweden, www.cellartis.com). All animal experiments were performed in
accordance with the Animal Welfare Ordinance and the Animal Welfare Act of Sweden
and approved by the Animal Experiments Ethics Committee of Gothenburg (approval no.
310–2005).
By conventional hybridoma technology, hybridoma cell lines were established producing
mAbs against hES cells. Mimotope analysis, immunoprecipitation, and mass-spectrometry
identified the target antigen as PODXL. The epitopes of both the monoclonal and the polyclon-
al antibody are in the extracellular portion of PODXL. Of four protein-coding PODXL splice
variants, the epitope sequence of the pAb matches three at 100% (PODXL 001, 005, and 201,
The Human Protein Atlas). The fourth splice variant matches at 87% (PODXL 202). The epi-
tope sequence of the mAb HES9 matches all splice variants 100%. [24,25]
Immunohistochemistry
Tumor-tissue microarray blocks were freshly cut into 4-μm sections. After deparaffinization in
xylene and rehydration through a gradually decreasing concentration of ethanol to distilled
water, slides were treated in a PreTreatment module (Lab Vision Corp., Fremont, CA, USA) in
Tris-Hcl (pH 8.5) buffer for 20 min at 98°C for antigen retrieval. Staining of sections was per-
formed in an Autostainer 480 (Lab Vision Corp., Fremont, CA, USA) by the Dako REAL EnVi-
sion Detection system, Peroxidase/DAB+, Rabbit/Mouse (Dako, Glostrup, Denmark). Tissues
were incubated with the mAb (dilution 1:800 = 8 μg/ml) and with pAb (dilution 1:250 =
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2.5 μg/ml) for one hour at room temperature. A sample of colon tissue served as a positive con-
trol in each staining series.
Evaluation of PODXL staining
PODXL expression by the mAb was evenly distributed in the cytoplasm and was often granu-
lar. By the pAb, PODXL expression was also cytoplasmic with no expression in the nuclei. In
many cases, a distinct membranous positivity emerged, even in cells with weak cytoplasmic
positivity. Cytoplasmic staining was scored as negative (0), weakly positive (1), moderately pos-
itive (2) or strongly positive (3) according to staining intensity. For cases with distinct membra-
nous staining by the pAb, the score was recorded as 3, regardless of cytoplasmic staining
intensity. The highest score of the triplicates of each sample was considered representative for
analysis. The stainings were scored by two independent investigators (K.S. and J.H.) without
knowledge of clinical data and outcome. Differing scores required determination of a consen-
sus score.
Statistical analyses
For statistical purposes, categories of PODXL expression were dichotomized for the mAb into
low (0–2) and high (3) and for the pAb into non-membranous (0–2) and membranous (3). A
categorization with three classes was created to study the two antibodies together: low (mAb,
low and pAb, non-membranous), moderate (either mAb, high or pAb, membranous), and
high (mAb, high and pAb, membranous). The Fischer exact-test or linear-by-linear association
test served in evaluating associations between PODXL expression and relevant clinocopatholo-
gical parameters. Survival analysis was done by the Kaplan-Meier method and compared by
the log-rank test. The Bonferroni correction was used for multiple comparisons by dividing the
probability level by the number of comparisons. The Cox regression proportional hazard
model served for uni- and multivariate survival analysis adjusted for age, gender, stage, lymph-
node ratio, and perivascular invasion. Interaction terms were considered, but with no signifi-
cant interactions found. The Cox model assumption of constant hazard ratios over time was
tested by including a time-dependent covariate separately for each testable variable at a time.
The assumption was met with all variables. Variables with p<0.05 in univariate analysis (age,
gender, T, N, stage, lymph node ratio (/<20%), grade, perineural invasion, perivascular inva-
sion, mAb, pAb and combination of mAb and pAb) were selected into the multivariate model,
retaining age and sex in all models. To simplify the model, stage and lymph node ratio (LNR)
were combined into a single variable. All tests were two-sided. A p-value of 0.05 or less was
considered significant. All statistical analyses were with SPSS version 20.0 (IBM SPSS Statistics,
version 20.0 for Windows; SPSS, Inc., Chicago, IL, USA, an IBM Company).
Results
Immunohistochemical staining
PODXL expression by the pAb was cytoplasmic in tumor cells, but in some cases, distinct
membranous expression was visible, not correlating with intensity of cytoplasmic expression.
Such a staining pattern was not apparent for the mAb: it was cytoplasmic and
evenly distributed.
PODXL staining by the pAb could be evaluated in 166 (98.8%) specimens: 13 (7.8%) show-
ing negative, 71 (42.8%) weak, 55 (33.1%) moderate, and 27 (16.3%) strong staining (Fig 1).
PODXL staining by the mAb could be evaluated in 165 (98.2%) specimens: 21 (12.7%) showing
negative, 69 (41.8%) weak, 39 (23.6%) moderate, and 36 (21.8%) strong staining (Fig 2).
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Association of PODXL expression with clinicopathological parameters
separately and combined
An association emerged between membranous PODXL expression by the pAb and T
(p = 0.045) and perineural invasion (p = 0.005). High PODXL expression by the mAb was asso-
ciated with poor differentiation (p = 0.033). PODXL expression correlated neither with age,
gender, stage, lymph-node ratio, tumor location (not shown), nor perivascular invasion
(Tables 1 and 2).
Fig 1. Immunohistochemical staining pattern of PODXL by polyclonal antibody HPA 2110 in pancreatic ductal adenocarcinoma.Representative
images of PODXL expression in pancreatic ductal adenocarcinoma. (A) PODXL-negative, (B) weak cytoplasmic positivity, (C) moderate cytoplasmic
positivity, and (D) strong and positive membranous positivity. Original magnification was x 400.
doi:10.1371/journal.pone.0129012.g001
Fig 2. Immunohistochemical staining pattern of PODXL bymonoclonal antibody HES9 in pancreatic ductal adenocarcinoma.Representative
images of PODXL expression in pancreatic ductal adenocarcinoma. (A) PODXL-negative, (B) weak cytoplasmic positivity, (C) moderate cytoplasmic
positivity, and (D) strong cytoplasmic positivity. Original magnification was x 400.
doi:10.1371/journal.pone.0129012.g002
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Table 1. Association of clinicopathological parameters and PODXL expression by polyclonal antibody HPA 2110.
Non-membranous Membranous
n(%) 93 (56.0) 73 (44.0) p-value
Age, years
<65 46 (49.5) 36 (49.3) 1.000
65 47 (50.5) 37 (50.7)
Gender
Male 52 (55.9) 40 (54.8) 1.000
Female 41 (44.1) 33 (45.2)
T
1 10 (11.0) 2 (2.7) 0.045
2 25 (27.5) 18 (24.7)
3 54 (59.3) 50 (68.5)
4 2 (2.2) 3 (4.1)
Missing 2
N
0 26 (28.6) 23 (31.5) 0.733
1 65 (71.4) 50 (68.5)
Missing 2
M
0 88 (95.7) 69 (95.8) 1.000
1 4 (4.3) 3 (4.2)
Missing 1 1
Stage (WHO)
IA 7 (7.9) 2 (2.8) 0.606
IB 9 (10.1) 9 (12.3)
IIA 10 (11.2) 10 (13.7)
IIB 58 (65.2) 46 (63.0)
III 0 (0.0) 3 (4.1)
IV 5 (5.6) 3 (4.1)
Missing 4
Lymph node ratio
<20% 68 (75.6) 56 (77.8) 0.852
20% 22 (24.4) 16 (22.2)
Missing 3 1
Grade
1 17 (21.2) 7 (11.1) 0.103
2 53 (66.3) 44 (69.8)
3 10 (12.5) 12 (19.1)
Missing 13 10
Perineural invasion
Yes 51 (67.1) 57 (87.7) 0.005
No 25 (22.9) 8 (12.3)
Missing 17 8
Perivascular invasion
Yes 23 (30.7) 26 (43.3) 0.151
No 52 (69.3) 34 (56.7)
Missing 18 13
Fischer exact-test was used for 2x2 tables and linear-by-linear association test for tables with more than two rows. Missing data excluded from
the analyses.
doi:10.1371/journal.pone.0129012.t001
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Table 2. Association of clinicopathological parameters and PODXL expression by monoclonal anti-
body HES9.
Low High
n(%) 129 (78.2) 36 (21.8) p-value
Age, years
<65 63 (48.8) 18 (50.0) 1.000
65 66 (51.2) 18 (50.0)
Gender
Male 73 (56.6) 18 (50.0) 0.570
Female 56 (43.4) 18 (50.0)
T
1 10 (7.9) 2 (5.7) 0.776
2 31 (24.4) 12 (34.3)
3 83 (65.4) 21 (60.0)
4 3 (2.3) 1 (2.9)
Missing 2 1
N
0 38 (29.9) 11 (30.6) 1.000
1 89 (70.1) 25 (69.4)
Missing 2
M
0 124 (96.9) 33 (94.3) 0.610
1 4 (3.1) 2 (5.7)
Missing 1 1
Stage (WHO)
IA 7 (5.6) 2 (5.6) 0.531
IB 15 (12.0) 3 (8.3)
IIA 16 (12.8) 4 (11.1)
IIB 80 (64.0) 24 (66.6)
III 2 (1.6) 1 (2.8)
IV 5 (4.0) 2 (5.6)
Missing 4
Lymph node ratio
<20% 96 (76.8) 27 (75.0) 0.826
20% 29 (23.2) 9 (25.0)
Missing 4
Grade
1 20 (18.2) 4 (12.5) 0.033
2 78 (70.9) 18 (56.3)
3 12 (10.9) 10 (31.2)
Missing 19 4
Perineural invasion
Yes 80 (73.4) 27 (87.1) 0.151
No 29 (26.6) 4 (12.9)
Missing 20 5
Perivascular invasion
Yes 32 (30.8) 15 (50.0) 0.081
No 72 (69.2) 15 (50.0)
(Continued)
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Analysis of combined PODXL expression with clinicopathological parameters showed sig-
nificant associations between high PODXL expression and poor differentiation (p = 0.014),
perineural invasion (p = 0.007) and perivascular invasion (p = 0.039). High expression failed to
correlate with age, gender, stage, or lymph node ratio (Table 3).
Survival analysis
For PDAC patients with membranous PODXL expression by the polyclonal antibody, cancer-
specific survival (CSS) was significantly worse (p = 0.006, Log-rank test); five-year CSS was
14.0% (95% CI 5.2–22.8%) for patients with membranous PODXL expression compared to
24.8% (95% CI 15.0–34.6%) for those with non-membranous expression (Fig 3).
PDAC patients with high PODXL expression by the monoclonal antibody showed a signifi-
cantly poorer CSS than did those with low expression (p = 0.001); five-year CSS for PDAC pa-
tients with low expression was 24.8% (95% CI 16.4–33.2%) and for those with high expression,
4.4% (95% CI -3.6–12.4%) (Fig 4).
A combination of mAb and pAb showed a significantly poorer CSS for PDAC patients with
high expression than for those with low expression (p = 0.001). No significant difference in
CSS appeared, however, between patients with moderate and high expression (p = 0.37), or be-
tween moderate and low expression (p = 0.020, Bonferroni correction used). Five-year CSS for
patients with low expression was 26.6% (95% CI 16.2–37.0%), with moderate expression 18.7%
(95% CI 6.5–30.9%) and with high expression 5.0% (95% CI -4.2–14.2%) (Fig 5).
Cox regression univariate analysis confirmed these results. High podocalyxin expression as-
sociated significantly with higher risk of death from PDAC by both the pAb (HR = 1.62; 95%
CI 1.12–2.33; p = 0.01) and the mAb (HR = 2.10, 95% CI 1.38–3.20; p<0.001). The combined
moderate expression of PODXL by both the mAb and pAb showed higher risk of death from
PDAC (HR = 1.56, 95% CI 1.02–2.40; p = 0.042), and the risk was even higher with combined
high expression (HR = 2.21, 95% CI 1.39–3.54; p<0.001). In multivariate analyses, adjusted for
age, gender, stage, lymph-node ratio, and perivascular invasion, membranous PODXL expres-
sion by the pAb and high PODXL expression by the mAb remained statistically significant.
The combined moderate and high expression of PODXL by both mAb and pAb also remained,
by multivariate analysis, statistically significant (Table 4).
Discussion
We demonstrate that in PDAC tissue overexpression of PODXL is an independent predictor of
poor prognosis, and that it associates with unfavorable clinicopathological factors. To our
knowledge, this is the first report of the prognostic value of PODXL expression in PDAC.
PODXL expression has been demonstrated in PDAC earlier [21,22]. Ney et al reported that
PODXL expression differentiates PDAC from adenocarcinomas occurring in the biliary tract
[21]. In their study, 44% of the PDAC specimens were positive for PODXL. Dallas et al [22]
showed immunopositivity for PODXL in 69% of the PDAC specimens. Staining intensity was
Table 2. (Continued)
Low High
n(%) 129 (78.2) 36 (21.8) p-value
Missing 25 6
Fischer exact-test was used for 2x2 tables and linear-by-linear association test for tables with more than
two rows. Missing data excluded from the analyses.
doi:10.1371/journal.pone.0129012.t002
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Table 3. Association of clinicopathological parameters and PODXL expression by polyclonal antibody HPA 2110 andmonoclonal antibody HES9
combined.
Low Moderate High
n (%) 87 (53.0) 45 (27.4) 32 (19.6) p-value
Age, years
<65 43 (49.4) 22 (48.9) 16 (50.0) 1.000
65 44 (50.6) 23 (51.1) 16 (50.0)
Gender
Male 50 (57.5) 24 (53.3) 17 (53.1) 0.689
Female 37 (42.5) 21 (46.7) 15 (46.9)
T
1 10 (11.7) 0 (0.0) 2 (6.3) 0.227
2 22 (25.9) 12 (26.7) 9 (28.1)
3 52 (61.2) 31 (68.9) 20 (62.5)
4 1 (1.2) 2 (4.4) 1 (3.1)
Missing 2
N
0 25 (29.4) 14 (31.1) 10 (31.3) 0.829
1 60 (70.6) 31 (68.9) 22 (68.7)
Missing 2
M
0 83 (96.5) 44 (97.8) 29 (93.5) 0.602
1 3 (3.5) 1 (2.2) 2 (6.5)
Missing 1 1
Stage (WHO)
IA 7 (8.4) 0 (0.0) 2 (6.3) 0.419
IB 8 (9.7) 8 (17.8) 2 (6.3)
IIA 10 (12.0) 6 (13.3) 4 (12.5)
IIB 54 (65.1) 28 (62.2) 21 (65.6)
III 0 (0.0) 2 (4.5) 1 (3.1)
IV 4 (4.8) 1 (2.2) 2 (6.3)
Missing 4
Lymph node ratio
<20% 63 (75.0) 35 (79.5) 24 (75.0) 0.907
20% 21 (25.0) 9 (20.5) 8 (25.0)
Missing 3 1
Gradus
1 16 (21.6) 5 (12.8) 3 (10.7) 0.014
2 51 (68.9) 28 (71.8) 17 (60.7)
3 7 (9.5) 6 (15.4) 8 (28.6)
Missing 13 6 4
Perineural invasion
Yes 48 (67.6) 32 (75.0) 26 (92.9) 0.007
No 23 (32.4) 8 (25.0) 2 (7.1)
Missing 16 5 4
Perivascular invasion
Yes 19 (27.1) 15 (41.7) 13 (48.1) 0.039
No 51 (72.9) 21 (58.3) 14 (51.9)
Missing 17 9 5
Linear-by-linear association test was used for this table. Missing data excluded from the analyses.
doi:10.1371/journal.pone.0129012.t003
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reported in neither study. In our series, immunopositivity for PODXL was more frequent:
92.2% of the specimens by the pAb and 87.3% by the mAb. One explanation could be differ-
ences in staining technique, in evaluation of the specimens, or in choice of cut-off points. In
our study both the polyclonal and the monoclonal antibody used show a similar proportion of
positivity. The antibody used in the study of Ney’s group differed from ours, whereas Dallas’
group used the same polyclonal antibody as we did.
We also show that immunostaining of PODXL by our new in-house mAb gives prognostic
results similar to those achieved by the commercial polyclonal antibody (HPA 2110, Atlas An-
tibodies, Stockholm, Sweden) in colorectal cancer [15,16]. Our results also are in line with the
studies of colorectal cancer by the same mAb [23,26].
It has been shown that, in cancer, poor prognosis associates with distinct membranous
PODXL expression, rather than cytoplasmic expression [15,27]. These findings are substantiat-
ed by earlier studies demonstrating that aberrant PODXL expression supports the disruption
of cell-to-cell and cell-to-extracellular matrix adhesions, and in this way promotes tumor
dissemination [28]. In cancer cells the staining pattern of the monoclonal antibody was differ-
ent, with mainly cytoplasmic expression in cancer cells with no distinct membranous
Fig 3. Membranous PODXL expression by polyclonal antibody HPA 2110 is a marker of poor prognosis in pancreatic ductal adenocarcinoma.
Cancer-specific survival analysis according to the Kaplan-Meier method for membranous PODXL expression by the polyclonal antibody HPA 2110 in
pancreatic ductal adenocarcinoma. Log-rank test was used here.
doi:10.1371/journal.pone.0129012.g003
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immunopositivity. The reason for this is unknown. In PDAC, the proportion of tumors with
high cytoplasmic or membranous PODXL expression was relatively large (21.8% and 44.0%,
respectively) compared to corresponding percentages in studies of colorectal [15], breast [14],
or urothelial bladder cancer [17].
The two antibodies used in this study recognize different epitopes in the extracellular region
of the PODXL molecule. This may explain why their expression patterns varied, and their case-
by-case expressions differed. Kaprio et al. hypothesized in the study of CRC that the pAb rec-
ognizes an active form of PODXL at the cell membrane, whereas the mAb recognizes overex-
pression of cytoplasmic PODXL [26]. In CRC, a subgroup with even worse prognosis was
identified when the mAb expression and the pAb expression of PODXL both were high and
membranous [26]. Here, similar evidence for PDAC was found.
Those patients, who had received neoadjuvant chemotherapy, were excluded from the
study, because it is not known how the chemotherapy would affect the tumor specimens. Only
a small difference existed between the two antibodies as prognostic markers: the hazard ratio
for risk of death was greater for patients with high PODXL expression by the mAb than for
those with membranous PODXL expression by the pAb. However, PODXL remained an
Fig 4. High PODXL expression bymonoclonal antibody HES9 is a marker of poor prognosis in pancreatic ductal adenocarcinoma.Cancer-specific
survival analysis according to the Kaplan-Meier method for high PODXL expression by the monoclonal antibody HES9 in pancreatic ductal adenocarcinoma.
Log-rank test was used here. MAb HES9 recognizes PODXL protein.
doi:10.1371/journal.pone.0129012.g004
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independent prognostic factor in multivariate analysis independent of the antibody. Scoring
was easier and staining differences were clearer by the mAb than by the pAb. Five-year CSS
was lower for patients with high PODXL expression by the mAb than for patients with mem-
branous PODXL expression by the pAb (4.4% vs. 14.0%). This supports the role of cytoplasmic
overexpression of PODXL as a marker of poor prognosis.
The strength of this study is a well-characterized, consecutive, and quite large patient cohort
with PDAC. Clinical follow-up and survival data were reliable and up-to-date. All histological
samples were re-evaluated by experienced pathologists; other types of pancreatic cancer other
than ductal adenocarcinoma were excluded. By the TMA technique, only a small area of each
tumor is evaluated and thus the staining result may not be representative. We tried to diminish
this possible error by taking cores from different parts of the tumor and altogether scored six
different spots for each tumor. Only a small proportion (1.2–1.8%) of our TMA spots were lost
due to technical reasons.
Fig 5. Concomitant positivity by two PODXL antibodies.Cancer-specific survival analysis according to the Kaplan-Meier method for combined
expression of PODXL by the polyclonal antibody HPA 2110 and the monoclonal antibody HES9. A categorization with three classes was created to study the
two antibodies together: low (mAb, low and pAb, non-membranous), moderate (either mAb, high or pAb, membranous), and high (mAb, high and pAb,
membranous).
doi:10.1371/journal.pone.0129012.g005
PODXL Is a Marker of Poor Prognosis in PDAC
PLOSONE | DOI:10.1371/journal.pone.0129012 June 8, 2015 12 / 15
Conclusion
To our knowledge, this is the first report to show that PODXL is an independent marker of
poor prognosis in PDAC. Both membranous expression of PODXL by a polyclonal antibody
(HPA 2110) and high cytoplasmic expression of PODXL by a monoclonal antibody (HES9) de-
fined groups with poor prognosis. To clarify the different expression patterns of the two anti-
bodies, we can speculate that they can either recognize different variants of PODXL in PDAC
or identify PODXL at different form in the cytoplasm or cellular membrane.
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